Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Turcot syndrome 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 6Paclitaxel 5Carboplatin 4Bevacizumab 3oregovomab 2Nivolumab 2Hyperthermic Intraperitoneal Chemotherapy 2Cisplatin 2tislelizumab 1spartalizumab 1rucaparib 1olaparib 1niraparib 1lenvatinib 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1anlotinib 1Surveys and Questionnaires 1Saline Solution 1Ramucirumab 1Platinum 1Nutrition Assessment 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Immunotherapy, Adoptive 1Glucose 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Ovarian Epithelial × denileukin diftitox × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡